Yingyi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yingyi Wang has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
Hui Tang
Department of Medical Oncology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China
10 shared publications- Chunmei Bai
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
7 shared publications Ruixuan Geng
6 shared publicationsTingting You
Department of Medical Oncology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China
6 shared publicationsChunmei Bai
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of China
5 shared publicationsRongrong Chen
5 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Association for Computing Machinery (ACM)
- p. 16769-16776
LungCURE: Benchmarking Multimodal Real-World Clinical Reasoning for Precision Lung Cancer Diagnosis and Treatment
- 9 November 2026
- Published by Association for Computing Machinery (ACM)
- p. 16769-16776
Open AccessLungCURE: Benchmarking Multimodal Real-World Clinical Reasoning for Precision Lung Cancer Diagnosis and Treatment
- Open Access
- 28 October 2026
- Published by BMJ in BMJ Health & Care Informatics
- Vol. 33 (1) , e102238
Identification and risk prediction of cancer symptom clusters based on integrated Chinese–Western multimodal data: a prospective real-world study protocol
Objectives To identify stable cancer symptom clusters (CSCs) phenotypes and trajectories in patients with breast and ovarian cancer, examine associations with traditional Chinese medicine (TCM) syndromes and develop prediction models.Methods A multicentre, prospective, longitudinal real-world cohort will enrol 2000 patients with breast cancer and 1000 patients with ovarian cancer. Data include clinical characteristics, symptoms, TCM syndrome information and multiomics data from subgroups. CSCs will be identified using exploratory factor analysis with bootstrap resampling; associations and trajectories will be analysed using regression and mixed-effects models. Prediction models will use LASSO(least absolute shrinkage and selection operator), random forest and XGBoost(extreme gradient boosting) with internal validation.Results Expected outcomes include stable CSCs phenotypes and clinically useful prediction models.Discussion This study integrates TCM syndrome differentiation to explore CSC heterogeneity and evolution in real-world settings.Conclusion Findings may support personalised symptom management and improve quality of life among patients with cancer.Trial registration number ChiCTR2500111873 (Approval time: 6 November 2025); ITMCTR2025001939 (registration time: 17 July 2025).
- 28 October 2026
- Published by BMJ in BMJ Health & Care Informatics
- Vol. 33 (1) , e102238
Open AccessIdentification and risk prediction of cancer symptom clusters based on integrated Chinese–Western multimodal data: a prospective real-world study protocol
Objectives To identify stable cancer symptom clusters (CSCs) phenotypes and trajectories in patients with breast and ovarian cancer, examine associations with traditional Chinese medicine (TCM) syndromes and develop prediction models.Methods A multicentre, prospective, longitudinal real-world cohort will enrol 2000 patients with breast cancer and 1000 patients with ovarian cancer. Data include clinical characteristics, symptoms, TCM syndrome information and multiomics data from subgroups. CSCs will be identified using exploratory factor analysis with bootstrap resampling; associations and trajectories will be analysed using regression and mixed-effects models. Prediction models will use LASSO(least absolute shrinkage and selection operator), random forest and XGBoost(extreme gradient boosting) with internal validation.Results Expected outcomes include stable CSCs phenotypes and clinically useful prediction models.Discussion This study integrates TCM syndrome differentiation to explore CSC heterogeneity and evolution in real-world settings.Conclusion Findings may support personalised symptom management and improve quality of life among patients with cancer.Trial registration number ChiCTR2500111873 (Approval time: 6 November 2025); ITMCTR2025001939 (registration time: 17 July 2025).
- 14 October 2026
- Published by Elsevier in Laboratory Investigation
Genomic and Transcriptomic Characterization of Angiosarcomas: Focus on Cardiac Origin
- 14 October 2026
- Published by Elsevier in Laboratory Investigation
Genomic and Transcriptomic Characterization of Angiosarcomas: Focus on Cardiac Origin
- Open Access
- 17 September 2026
- Published by Springer Nature in Scientific Reports
Development of a symptom cluster scale for breast cancer patients undergoing adjuvant chemotherapy based on the Chinese population: a Delphi-based study
- 17 September 2026
- Published by Springer Nature in Scientific Reports
Open AccessDevelopment of a symptom cluster scale for breast cancer patients undergoing adjuvant chemotherapy based on the Chinese population: a Delphi-based study
- Open Access
Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic Cancer: A Prospective Large‐Cohort Study
Current methods for assessing treatment response and prognosis in pancreatic ductal adenocarcinoma (PDAC) have intrinsic limitations, necessitating novel biomarkers. This prospective cohort study evaluated whether early dynamic changes in ctDNA predict treatment efficacy and outcomes in advanced PDAC. We enrolled 127 patients receiving first‐line therapy, with peripheral blood collected at baseline (B1), first response assessment (B2), and subsequent timepoints for high‐depth next‐generation sequencing. The ctDNA detection rates significantly decreased from 78.7% at B1 to 55.7% at B2. Elevated CA19‐9 levels, ctDNA, and maximum somatic allele frequency (MSAF) were associated with disease progression. Higher B1 ctDNA and MSAF correlated with shorter progression‐free survival (PFS) and overall survival (OS), consistent with an external validation cohort. The Cox regression confirmed that MSAF and CA19‐9 were significant prognostic factors. In CA19‐9‐negative PDAC patients, increased ctDNA levels were associated with shorter PFS. This study demonstrated that high ctDNA levels and MSAF values are indicators of poor prognosis. Conversely, a decrease or clearance of ctDNA and MSAF suggests better disease control. In addition, in CA19‐9‐negative patients, dynamic ctDNA monitoring was able to indicate disease control and predict patient prognosis.
Open AccessDynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic Cancer: A Prospective Large‐Cohort Study
Current methods for assessing treatment response and prognosis in pancreatic ductal adenocarcinoma (PDAC) have intrinsic limitations, necessitating novel biomarkers. This prospective cohort study evaluated whether early dynamic changes in ctDNA predict treatment efficacy and outcomes in advanced PDAC. We enrolled 127 patients receiving first‐line therapy, with peripheral blood collected at baseline (B1), first response assessment (B2), and subsequent timepoints for high‐depth next‐generation sequencing. The ctDNA detection rates significantly decreased from 78.7% at B1 to 55.7% at B2. Elevated CA19‐9 levels, ctDNA, and maximum somatic allele frequency (MSAF) were associated with disease progression. Higher B1 ctDNA and MSAF correlated with shorter progression‐free survival (PFS) and overall survival (OS), consistent with an external validation cohort. The Cox regression confirmed that MSAF and CA19‐9 were significant prognostic factors. In CA19‐9‐negative PDAC patients, increased ctDNA levels were associated with shorter PFS. This study demonstrated that high ctDNA levels and MSAF values are indicators of poor prognosis. Conversely, a decrease or clearance of ctDNA and MSAF suggests better disease control. In addition, in CA19‐9‐negative patients, dynamic ctDNA monitoring was able to indicate disease control and predict patient prognosis.
- Open Access
- 21 September 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (9) , e010812
Autophagy inhibition improves the efficacy of anlotinib and PD-1 inhibitors in the treatment of NSCLC
Background: Cancer-associated fibroblasts (CAFs) are major non-tumor cellular components of the tumor microenvironment (TME) and are closely related to immune suppression. The enhancement of anti-programmed cell death protein-1 (PD-1) efficacy by antiangiogenic tyrosine kinase receptor inhibitors (TKIs) is partly due to the elimination of CAFs, which improves the immunosuppressive microenvironment. However, it remains unclear whether antiangiogenic TKIs regulate the autophagy of CAFs, thereby affecting the immunotherapy response. Methods: We first examined the effects of autophagy inhibition and anlotinib on the TME and immunotherapy response via animal experiments. Then, CAF models were established in vitro. The effects and mechanisms of autophagy inhibition on the efficacy of anlotinib and CAFs were further explored in vitro. To specifically validate the role of CAF autophagy, we additionally constructed LLC tumor-bearing mouse models co-implanted with CAFs transfected with ATG5-targeting siRNA or non-targeting control siRNA. Results: In anti-PD-1-resistant (LLC) and CAF-rich (LA795+MSC) non-small cell lung cancer models, the autophagy inhibitor chloroquine significantly enhanced anlotinib+anti-PD-1 efficacy—likely by inducing more apoptosis of CAFs and M2 macrophages, reshaping the TME to promote CD8+T cell infiltration. After ATG5 knockdown (autophagy inhibition) in CAFs, the efficacy-enhancing effect of anti-PD-1 therapy was significantly attenuated versus control, confirming CAF autophagy is core to TME regulation. In vitro, anlotinib induced CAF autophagy via AKT/mTOR inhibition; inhibiting CAF autophagy enhanced anlotinib-induced CAF apoptosis and impaired CAFs’ ability to recruit M2 macrophages. Conclusions: Autophagy inhibition enhances the effects of antiangiogenic TKIs on tumor cells and CAFs and directly or indirectly regulates the TME, which might explain why autophagy inhibition enhances the efficacy of antiangiogenic TKIs combined with anti-PD-1 therapy.
- 21 September 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (9) , e010812
Open AccessAutophagy inhibition improves the efficacy of anlotinib and PD-1 inhibitors in the treatment of NSCLC
Background: Cancer-associated fibroblasts (CAFs) are major non-tumor cellular components of the tumor microenvironment (TME) and are closely related to immune suppression. The enhancement of anti-programmed cell death protein-1 (PD-1) efficacy by antiangiogenic tyrosine kinase receptor inhibitors (TKIs) is partly due to the elimination of CAFs, which improves the immunosuppressive microenvironment. However, it remains unclear whether antiangiogenic TKIs regulate the autophagy of CAFs, thereby affecting the immunotherapy response. Methods: We first examined the effects of autophagy inhibition and anlotinib on the TME and immunotherapy response via animal experiments. Then, CAF models were established in vitro. The effects and mechanisms of autophagy inhibition on the efficacy of anlotinib and CAFs were further explored in vitro. To specifically validate the role of CAF autophagy, we additionally constructed LLC tumor-bearing mouse models co-implanted with CAFs transfected with ATG5-targeting siRNA or non-targeting control siRNA. Results: In anti-PD-1-resistant (LLC) and CAF-rich (LA795+MSC) non-small cell lung cancer models, the autophagy inhibitor chloroquine significantly enhanced anlotinib+anti-PD-1 efficacy—likely by inducing more apoptosis of CAFs and M2 macrophages, reshaping the TME to promote CD8+T cell infiltration. After ATG5 knockdown (autophagy inhibition) in CAFs, the efficacy-enhancing effect of anti-PD-1 therapy was significantly attenuated versus control, confirming CAF autophagy is core to TME regulation. In vitro, anlotinib induced CAF autophagy via AKT/mTOR inhibition; inhibiting CAF autophagy enhanced anlotinib-induced CAF apoptosis and impaired CAFs’ ability to recruit M2 macrophages. Conclusions: Autophagy inhibition enhances the effects of antiangiogenic TKIs on tumor cells and CAFs and directly or indirectly regulates the TME, which might explain why autophagy inhibition enhances the efficacy of antiangiogenic TKIs combined with anti-PD-1 therapy.
- Open Access
- 26 June 2025
- Published by Elsevier in Lung Cancer
- Vol. 206
MRD status combined with TNM staging optimizes postoperative prognostic stratification in non-small cell lung cancer: a meta-analysis and systematic review
- 26 June 2025
- Published by Elsevier in Lung Cancer
- Vol. 206
Open AccessMRD status combined with TNM staging optimizes postoperative prognostic stratification in non-small cell lung cancer: a meta-analysis and systematic review
- 25 December 2024
- Published by Elsevier in Lung Cancer
- Vol. 199, 108068
Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53
- 25 December 2024
- Published by Elsevier in Lung Cancer
- Vol. 199, 108068
Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53
- Open Access
- 24 November 2024
- Published by Wiley in Thoracic Cancer
- Vol. 16 (1)
Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study
Purpose: Our study aimed to comprehensively describe the features of peripheral blood multiple immune cell phenotypes in solid tumor patients during pretreatment and after immunotherapy, providing a more convenient approach for studying the prognosis of immunotherapy in different solid tumor patients.Methods: We prospectively recruited patients with advanced solid tumors from Peking Union Medical College Hospital (PUMCH) between February 2023 and April 2024. Using multicolor flow cytometry, our study comprehensively observed and described the signatures of peripheral blood lymphocyte subsets including activation, proliferation, function, naïve memory, and T cell exhaustion immune cell subsets in this population of pretreatment and after immunotherapy.Results: Our study enrolled 59 advanced solid tumor patients with immunotherapy and 59 healthy controls were matched by age and gender. The results demonstrated a marked upregulation in the expression of lymphocyte activation markers CD38 and HLA‐DR, as well as exhaustion and proliferation markers PD‐1 and Ki67, in solid tumor patients compared to healthy controls. After immune checkpoint blockade (ICB) treatment, mainly the expression of Ki67CD4+T and HLA‐DRCD38CD4+T, was significantly upregulated compared to pretreatment levels (p = 0.017, p = 0.019, respectively). We further found that gynecological tumors with better prognoses had higher baseline activation levels of CD4+ T cells compared to other solid tumors with poorer prognoses.Conclusion: Our study elucidated the characteristics of different lymphocyte subsets in the peripheral blood of solid tumor patients. Further research revealed changes in the phenotypes of different lymphocyte subsets after ICIs treatment, with the activated phenotype of CD4+ T cells playing a crucial role in the antitumor effect. This lays the groundwork for further exploration of prognostic biomarkers and predictive models for cancer patients with immunotherapy.
- 24 November 2024
- Published by Wiley in Thoracic Cancer
- Vol. 16 (1)
Open AccessImmune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study
Purpose: Our study aimed to comprehensively describe the features of peripheral blood multiple immune cell phenotypes in solid tumor patients during pretreatment and after immunotherapy, providing a more convenient approach for studying the prognosis of immunotherapy in different solid tumor patients.Methods: We prospectively recruited patients with advanced solid tumors from Peking Union Medical College Hospital (PUMCH) between February 2023 and April 2024. Using multicolor flow cytometry, our study comprehensively observed and described the signatures of peripheral blood lymphocyte subsets including activation, proliferation, function, naïve memory, and T cell exhaustion immune cell subsets in this population of pretreatment and after immunotherapy.Results: Our study enrolled 59 advanced solid tumor patients with immunotherapy and 59 healthy controls were matched by age and gender. The results demonstrated a marked upregulation in the expression of lymphocyte activation markers CD38 and HLA‐DR, as well as exhaustion and proliferation markers PD‐1 and Ki67, in solid tumor patients compared to healthy controls. After immune checkpoint blockade (ICB) treatment, mainly the expression of Ki67CD4+T and HLA‐DRCD38CD4+T, was significantly upregulated compared to pretreatment levels (p = 0.017, p = 0.019, respectively). We further found that gynecological tumors with better prognoses had higher baseline activation levels of CD4+ T cells compared to other solid tumors with poorer prognoses.Conclusion: Our study elucidated the characteristics of different lymphocyte subsets in the peripheral blood of solid tumor patients. Further research revealed changes in the phenotypes of different lymphocyte subsets after ICIs treatment, with the activated phenotype of CD4+ T cells playing a crucial role in the antitumor effect. This lays the groundwork for further exploration of prognostic biomarkers and predictive models for cancer patients with immunotherapy.
- Open Access
Impact of the gut microbiome on response and toxicity to chemotherapy in advanced esophageal cancer